SBIO vs. GREK
SBIO (ALPS Medical Breakthroughs ETF) and GREK (Global X MSCI Greece ETF) are both exchange-traded funds - SBIO is a Health & Biotech Equities fund tracking the S-Network Medical Breakthroughs Index, while GREK is a Emerging Markets Equities fund tracking the MSCI All Greece Select 25-50. Both are passively managed. Over the past 10 years, SBIO returned 8.36%/yr vs 14.76%/yr for GREK. At a 0.29 correlation, their price movements are largely independent. SBIO charges 0.50%/yr vs 0.58%/yr for GREK.
Performance
SBIO vs. GREK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO achieves a -1.72% return, which is significantly lower than GREK's 10.53% return. Over the past 10 years, SBIO has underperformed GREK with an annualized return of 8.36%, while GREK has yielded a comparatively higher 14.76% annualized return.
SBIO
- 1D
- -0.36%
- 1M
- -9.33%
- YTD
- -1.72%
- 6M
- -2.48%
- 1Y
- 59.38%
- 3Y*
- 16.69%
- 5Y*
- 1.33%
- 10Y*
- 8.36%
GREK
- 1D
- 1.58%
- 1M
- 1.44%
- YTD
- 10.53%
- 6M
- 11.07%
- 1Y
- 36.15%
- 3Y*
- 31.41%
- 5Y*
- 23.55%
- 10Y*
- 14.76%
SBIO vs. GREK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | -1.72% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 50.30% | -11.81% | 45.67% |
GREK Global X MSCI Greece ETF | 10.53% | 76.11% | 9.53% | 42.72% | 3.64% | 6.14% | -13.89% | 50.20% | -31.25% | 34.80% |
Correlation
The correlation between SBIO and GREK is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.33 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2015 | 0.29 |
SBIO vs. GREK - Sectors Allocation Comparison
Sectors
SBIO
GREK
Healthcare
-
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Industrials
-
Real Estate
-
Technology
-
-
Utilities
-
Financial Services
Healthcare
SBIO
GREK
-
Basic Materials
SBIO
-
GREK
Communication Services
SBIO
-
GREK
Consumer Cyclical
SBIO
-
GREK
Consumer Defensive
SBIO
-
GREK
Energy
SBIO
-
GREK
Industrials
SBIO
-
GREK
Real Estate
SBIO
-
GREK
Technology
SBIO
-
GREK
-
Utilities
SBIO
-
GREK
Financial Services
SBIO
GREK
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO vs. GREK — Risk / Return Rank
SBIO
GREK
SBIO vs. GREK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Global X MSCI Greece ETF (GREK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO | GREK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.51 | ||
| Sortino ratioReturn per unit of downside risk | +0.59 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.27 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 4.72 | 1.70 | +3.01 |
| Martin ratioReturn relative to average drawdown | 13.54 | 5.27 | +8.27 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO | GREK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.02 | 1.51 | +0.51 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.04 | 0.97 | -0.93 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.25 | 0.50 | -0.25 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.16 | +0.05 |
Drawdowns
SBIO vs. GREK - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, smaller than the maximum GREK drawdown of -79.50%. Use the drawdown chart below to compare losses from any high point for SBIO and GREK.
Loading charts...
Drawdown Indicators
| SBIO | GREK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.06% | -79.50% | +16.44% |
Max Drawdown (1Y)Largest decline over 1 year | -12.66% | -21.32% | +8.66% |
Max Drawdown (3Y)Largest decline over 3 years | -42.44% | -22.63% | -19.81% |
Max Drawdown (5Y)Largest decline over 5 years | -53.10% | -30.46% | -22.64% |
Max Drawdown (10Y)Largest decline over 10 years | -63.06% | -57.04% | -6.02% |
Current DrawdownCurrent decline from peak | -17.90% | -5.63% | -12.27% |
Average DrawdownAverage peak-to-trough decline | -28.43% | -45.30% | +16.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.40% | 6.88% | -2.48% |
Volatility
SBIO vs. GREK - Volatility Comparison
ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.87% compared to Global X MSCI Greece ETF (GREK) at 8.07%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than GREK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO | GREK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.87% | 8.07% | +1.80% |
Volatility (6M)Calculated over the trailing 6-month period | 22.68% | 20.47% | +2.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.62% | 24.14% | +5.48% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.56% | 24.41% | +9.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.18% | 29.84% | +3.34% |
SBIO vs. GREK - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than GREK's 0.58% expense ratio.
Dividends
SBIO vs. GREK - Dividend Comparison
SBIO has not paid dividends to shareholders, while GREK's dividend yield for the trailing twelve months is around 3.13%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GREK Global X MSCI Greece ETF | 3.13% | 3.46% | 4.63% | 2.61% | 2.82% | 2.16% | 2.62% | 2.25% | 2.41% | 2.13% | 1.95% | 1.52% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% | 0.00% | 0.00% |
Frequently Asked Questions
SBIO and GREK have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBIO has higher volatility (9.87%) compared to GREK (8.07%). In terms of maximum drawdown, SBIO dropped -63.06% vs GREK's -79.50%.
On 10-year performance, GREK leads with 14.76% vs 8.36% for SBIO. On fees, SBIO is cheaper at 0.50% per year. On volatility, GREK has been the lower-risk option at 8.07%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, GREK has performed better with a 14.76% return vs 8.36%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
SBIO is cheaper with a 0.50% expense ratio, compared with 0.58% for GREK.
GREK has the higher dividend yield at 3.13%, compared with 0.00% for SBIO.
SBIO is categorized as Health & Biotech Equities, while GREK is Emerging Markets Equities. SBIO tracks S-Network Medical Breakthroughs Index, while GREK tracks MSCI All Greece Select 25-50. They also come from different issuers: SS&C and Global X. Their fees differ too: 0.50% for SBIO and 0.58% for GREK.
SBIO currently has the higher Sharpe Ratio (2.02 vs 1.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SBIO and GREK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer